Greer Completes Enrollment of Phase III Allergy Trial
Posted on: Friday, 27 June 2008, 03:02 CDT
Greer has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen.
Between March and June 2008, 556 patients were screened for the randomized, double-blind, placebo-controlled trial, of which 430 were enrolled.
The participants will be observed at 31 clinical sites across the country. The trial will last approximately seven months, ending in mid-October 2008 to coincide with the completion of the short ragweed pollen season.
The treatment course will consist of daily, self-administered doses of Greer's standardized short ragweed pollen extract or placebo using a metered dosing device developed specifically for the studies. Participants range in ages from 18-55 and have a history of moderate to severe allergic rhinoconjunctivitis attributable to short ragweed pollen for at least two years. Patients with a history of mild intermittent asthma were also selected.
Robert Esch, executive vice president of R&D at Greer, said: "This study is significant because it is the first large Phase III trial conducted in the US for the sublingual-oral administration of liquid allergenic extracts. It is vital to Greer's efforts to bring an FDA-approved sublingual-oral immunotherapy treatment to the US."
Source: Datamonitor
Related Articles
- Greer Completes Enrollment for Pivotal Phase III Clinical Trial Evaluating the Efficacy of Sublingual-Oral Immunotherapy for Treating Short Ragweed Allergies
- Greer's Sublingual-Oral Immunotherapy Clinical Trials Supporting the Safety of Home-Administered Treatment Published in the Annals of Allergy, Asthma and Immunology
- Greer Launches Phase III Trial to Study Efficacy of Sublingual-Oral Immunotherapy in Patients With Allergic Rhinoconjunctivitis
- Greer Reports Favorable Results of Phase IIb Clinical Trial of Short Ragweed Sublingual-Oral Immunotherapy at American Academy of Allergy Asthma and Immunology Annual Meeting
- Avigen Completes Phase I Trial for AV650, an Oral Treatment for Neuromuscular Spasm and Spasticity; Phase I Study Includes Lack of Sedation Testing for AV650
- TorreyPines Therapeutics Completes Phase I Trial for NGX426, a Novel Oral Treatment for Pain
- TorreyPines Therapeutics Initiates Phase I Clinical Trial of NGX426, a Novel Oral Therapy for Migraine and Neuropathic Pain
- Chimerix Announces Initiation of Phase I Clinical Trials of CMX001, an Oral Treatment for Smallpox Infection
- Greer to Present Findings of Sublingual-Oral Immunotherapy Safety and Dosing Trials at 2006 American Academy of Allergy Asthma and Immunology Meeting
- Advitech Completes Recruitment for Its Second Clinical Study on Oral Treatment for Psoriasis
 |
 |
User Comments (0)
RSS Feeds